Stock Price Prediction

CNTB stock has potential upside due to its strategic focus on its lead asset, rademikibart, which is advancing toward Phase 3 trials in asthma and atopic dermatitis. The termination of the Pfizer deal optimizes resources, extending its cash runway, but liquidity concerns remain after a ~27% YoY drop in investments. Current price levels may reflect undervaluation if regulatory milestones are achieved, but risks persist.

CNTB stock faces bearish sentiment due to its financial struggles, including a ~27% YoY drop in liquidity and investments, and the termination of its Pfizer deal, which signals resource constraints. The stock recently slumped 4.1% after the announcement, reflecting market concerns over its cash runway and paused pre-clinical programs. With limited near-term catalysts, CNTB may face further downside pressure below $1.50 if liquidity issues persist.